Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $16.75 Analyst target: $25.10 Upside: 49.85%
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.
See the full interactive analysis & chart →Informational only — not investment advice.